Oncotarget

Research Papers:

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3

Filipa Quintela Vieira _, Pedro Costa-Pinheiro, Diogo Almeida-Rios, Inês Graça, Sara Monteiro-Reis, Susana Simões-Sousa, Isa Carneiro, Elsa Joana Sousa, Maria Inês Godinho, Fátima Baltazar, Rui Henrique and Carmen Jerónimo

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:13644-13657. https://doi.org/10.18632/oncotarget.3767

Metrics: PDF 1440 views  |   HTML 1791 views  |   ?  


Abstract

Filipa Quintela Vieira1,2, Pedro Costa-Pinheiro1,*, Diogo Almeida-Rios1,5,*, Inês Graça1,2, Sara Monteiro-Reis1,5, Susana Simões-Sousa3,4, Isa Carneiro1,5, Elsa Joana Sousa1, Maria Inês Godinho6, Fátima Baltazar3,4, Rui Henrique1,5,7,*,#, Carmen Jerónimo1,7*,#

1Cancer Biology and Epigenetics Group – Research Center, Portuguese Oncology Institute – Porto, Portugal

2School of Allied Health Sciences (ESTSP), Polytechnic of Porto, Portugal

3Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal

4ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal

5Departments of Pathology, Portuguese Oncology Institute – Porto, Portugal

6Departments of Immunology, Portuguese Oncology Institute – Porto, Portugal

7Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS) – University of Porto, Portugal

*These authors have contributed equally to this work

#These authors share senior authorship

Correspondence to:

Carmen Jerónimo, e-mail: carmenjeronimo@ipoporto.min-saude.pt

Keywords: SMYD3, prostate cancer, histone methyltransferase, SET domain, cyclin D2

Received: November 24, 2014     Accepted: April 13, 2015     Published: April 25, 2015

ABSTRACT

Prostate cancer (PCa) is one of the most incident cancers worldwide but clinical and pathological parameters have limited ability to discriminate between clinically significant and indolent PCa. Altered expression of histone methyltransferases and histone methylation patterns are involved in prostate carcinogenesis. SMYD3 transcript levels have prognostic value and discriminate among PCa with different clinical aggressiveness, so we decided to investigate its putative oncogenic role on PCa.

We silenced SMYD3 and assess its impact through in vitro (cell viability, cell cycle, apoptosis, migration, invasion assays) and in vivo (tumor formation, angiogenesis). We evaluated SET domain’s impact in PCa cells’ phenotype. Histone marks deposition on SMYD3 putative target genes was assessed by ChIP analysis.

Knockdown of SMYD3 attenuated malignant phenotype of LNCaP and PC3 cell lines. Deletions affecting the SET domain showed phenotypic impact similar to SMYD3 silencing, suggesting that tumorigenic effect is mediated through its histone methyltransferase activity. Moreover, CCND2 was identified as a putative target gene for SMYD3 transcriptional regulation, through trimethylation of H4K20.

Our results support a proto-oncogenic role for SMYD3 in prostate carcinogenesis, mainly due to its methyltransferase enzymatic activity. Thus, SMYD3 overexpression is a potential biomarker for clinically aggressive disease and an attractive therapeutic target in PCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3767